NCT07001540View on ClinicalTrials.gov

Evaluation of the Efficacy and Safety of Polatuzumab Vedotin Combined With Rituximab, Gemcitabine, and Oxaliplatin (Pola-R-GemOx) as Salvage Therapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Patients Ineligible for Autologous Transplantation

PHASE2RecruitingINTERVENTIONAL
Enrollment

130

Participants

Timeline

Start Date

May 8, 2025

Primary Completion Date

November 15, 2027

Study Completion Date

November 15, 2027

Conditions
Diffuse Large B-Cell Lymphoma
Interventions
DRUG

Polatuzumab Vedotin combined with Rituximab, Gemcitabine, and Oxaliplatin (Pola-R- GemOx)

Polatuzumab Vedotin combined with Rituximab, Gemcitabine, and Oxaliplatin (Pola-R-GemOx)

Trial Locations (1)

200231

RECRUITING

Fudan University Shanghai Cancer Center, Shanghai

All Listed Sponsors
collaborator

Fujian Cancer Hospital

OTHER_GOV

lead

Fudan University

OTHER